Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arketamine hydrochloride
- Development stage
- Phase 2
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Arketamine hydrochloride (HS-10519) is the (R)-enantiomer of the racemic anesthetic ketamine, currently under development as a rapid-acting antidepressant. Unlike esketamine (the S-enantiomer), which is a potent N-methyl-D-aspartate (NMDA) receptor antagonist, arketamine exhibits lower affinity for the NMDA receptor but has shown potent and long-lasting antidepressant-like effects in preclinical models, potentially with a superior safety profile regarding dissociative and psychotomimetic side effects. Its mechanism of action is thought to involve the activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and the brain-derived neurotrophic factor (BDNF)-mTOR signaling pathway. HS-10519 is specifically being investigated for major depressive disorder (MDD) in patients with acute suicidal ideation or behavior.
- Other names
- r-ketamine hydrochloride(R)-ketamine hydrochloridearketamine
02
Targets
DRD2 (Dopamine D2 Receptor)NTRK2 (Tropomyosin-related kinase receptor type B)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on arketamine hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arketamine hydrochloride.